Status:
COMPLETED
Total Hip Replacement Study Of GSK576428 (Fondaparinux Sodium)
Lead Sponsor:
GlaxoSmithKline
Conditions:
Thrombosis, Venous
Eligibility:
All Genders
20+ years
Phase:
PHASE3
Brief Summary
This study is requested by PMDA to confirm the optimal dose for THR (total hip replacement).
Eligibility Criteria
Inclusion
- Patients undergoing either an elective primary THR (total hip replacement) surgery or a revision of a THR.
Exclusion
- Active, clinically significant bleeding (excluding drainage).
Key Trial Info
Start Date :
January 30 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 18 2006
Estimated Enrollment :
114 Patients enrolled
Trial Details
Trial ID
NCT00320398
Start Date
January 30 2006
End Date
July 18 2006
Last Update
September 4 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site